• About us
• Contact

Advertisement

Document › Details

ITM Isotope Technologies Munich SE. (12/21/23). "Press Release: ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference". Garching.

	Region	San Francisco, CA
	Country	United States (USA)
	Organisation	ITM Isotope Technologies Munich SE
	Today	Isotopen Technologien München AG
	Group	ITM (Group)
	Organisation 2	J.P. Morgan Securities LLC
	Group	JPMorgan Chase (Group)
	Product	J.P. Morgan 42nd Annual Healthcare Conference 2024 San Francisco
	Product 2	RADIOPHARMACEUTICAL (RPT)
	Person	Schuster, Steffen (ITM Isotopen Technologien München 201603 CEO)
	Person 2	Maleck, Klaus (ITM 202309 CFO before TETEC AG + Evotec + BioGeneriX)

ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster and CFO, Dr. Klaus Maleck will participate in the 42ndAnnual J.P. Morgan Healthcare Conference in San Francisco. Steffen Schuster will present a corporate overview on Tuesday, January 9, 2024, at 9:00 am PST.


- End -


ITM Isotope Technologies Munich SE

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.
www.itm-radiopharma.com


ITM Contact

Corporate Communications

Svenja Gärtner / Gerrit Siegers
Phone: +49 89 329 8986 1502
Email: communications@itm-radiopharma.com

Investor Relations

Ben Orzelek
Phone: +49 89 329 8986 1009
Email: investors@itm-radiopharma.com

Record changed: 2024-03-14

Advertisement

More documents for ITM (Group)

• [1] ITM Isotope Technologies Munich SE. (6/20/24). "Press Release: ITM Appoints Dr. Andrew Cavey as CEO to Lead Organization in its Next Stage of Growth". Garching....
• [2] ITM Isotope Technologies Munich SE. (6/6/24). "Press Release: ITM Raises €188m to Enhance Radiopharmaceutical Pipeline and to Strengthen Leading Position in Medical Radioisotope Manufacturing". Garching....
• [3] ITM Isotope Technologies Munich SE. (2/1/24). "Press Release: ITM Obtains Manufacturing License in the U.S.". Garching & Princeton, NJ....
• [4] ITM Isotope Technologies Munich SE. (1/30/24). "Press Release: ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program". Garching & Vancouver, BC....
• [5] ITM Isotope Technologies Munich SE. (7/31/23). "Press Release: ITM and Point Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177". Garching & Indianapolis, IN....
• [6] ITM Isotope Technologies Munich SE. (6/5/23). "Press Release: ITM Announces €255m Investment Round, Plans to Advance Radiopharmaceutical Pipeline and to Expand Radioisotope Production Capacities". Garching....
• [7] ITM Isotope Technologies Munich SE. (4/17/23). "Press Release: ITM Appoints Roger Estafanos as U.S. General Manager and Expands Presence with Opening of U.S. Headquarters in Princeton, New Jersey". Garching & Princeton, NJ....
• [8] ITM Isotope Technologies Munich SE. (3/22/22). "Press Release: ITM Receives EUR 33 Million Equity Investment to Advance Precision Oncology Pipeline of Targeted Radiopharmaceuticals". Garching....
• [9] ITM Isotope Technologies Munich SE. (1/5/22). "Press Release: ITM Isotope Technologies Munich to Present at the 40th Annual J.P. Morgan Healthcare Conference". Garching....
• [10] ITM Isotopen Technologien München AG. (6/10/21). "Press Release: ITM Announces EUR 25 Million (USD 30 M) Private Equity Financing to Support Advancement of Proprietary Precision Oncology Pipeline"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.